

Defense Health Agency SBIR/STTR Program

Agency Introduction

- DHA is a joint, integrated Combat Support Agency that enables the Military Departments to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime
- Supports the delivery of integrated, affordable, and high quality health services to 9.6 million Military Health System (MHS) beneficiaries
- Supports the Assistant Secretary of Defense for Health Affairs in management and oversight of Defense Health Program (DHP) RDT&E appropriation (does not execute research efforts)
- Manages and executes Science & Technology funds, ensuring they align to requirements and are positioned to transition into formal product development efforts





MISSION

The Defense Health Agency supports our Nation by improving health and building readiness – making extraordinary experiences ordinary and exceptional outcomes routine.

VISION

Unrelenting pursuit of excellence as we care for our joint force and those that we are privileged to serve.

Anytime, Anywhere—Always.

PRIORITIES

Enabling Combat Support to the Joint Force in Competition, Crisis, or Conflict


Building a Modernized, Integrated, and Resilient Health Delivery System

Dedicated and Inspired Teams of Professionals Driving Military Health's Next Evolution





The DHA in the Department of Defense







DHA SBIR/STTR Programs

- Provide Phase I and Phase II funding opportunities
- Direct to Phase II, Phase II Enhancement, and Sequential Phase II mechanisms are also utilized on a limited basis
- In-house transition assistance through a Technical Assistance Advocate begins at the awarding of a Phase I contract
- Topics align to broader research program areas, which is important to supporting transition into product development
- Topics typically appear on the DoD SBIR/STTR main BAA cycles, but special cycles may be issued; be certain to join the DoD SBIR/STTR mailing list on DSIP!





Biomedical R&D Investment Approach

Primarily targeting areas, or environments, that are militarily unique for which there are limited or no commercial partners or interests

- The DoD <u>leads</u> in key biomedical research areas: e.g., prolonged field care, en route care, forward surgical/intensive critical care, hemorrhage control and blood products
- The DoD <u>leverages</u> in areas where commercial technologies exist and can be tailored for military use: e.g., medical simulation and training, diagnostic systems, pain management, infectious diseases
- The DoD <u>watches</u> areas of emerging interest: e.g., tech areas like Artificial Intelligence and Machine Learning





RDT&E Major Investment Areas



Military Operational Medicine

- Musculoskeletal injury prevention and reduction
- Blunt, blast, accelerative, and neurosensory injury prevention and readiness
- Psychological health & resilience
- Performance in extreme environments
- Optimized cognition & fatigue mitigation

Combat Casualty Care

- Neurotrauma
- Hemorrhage control & battlefield resuscitation
- Prolonged Care
- Severe burn
- En Route Care
- · Autonomous care & evacuation
- · Radiation health countermeasures
- · Military medical photonics

Military Infectious Diseases

- Viral
- Bacterial
- Wound Healing





Recent DHA SBIR/STTR Topic Examples

Military Infectious Diseases

- Rapid Purification for Therapeutic Use of Bacteriophages That Target Gram-Negative Bacterial Species
- Material Solutions to Bacteriophage Stabilization/Application in Austere Environments

Military Operational Medicine

- Wireless Core Temperature Measurement during Extreme Environmental Exposure
- Portable Technology to Assess Ankle Instability

Combat Casualty Care

- Development and Testing of Dual-lumen Femoral Cannula with Echogenic Material for Faster, Safer, and More Reliable Delivery of Extracorporeal Life Support during Prolonged Field Care
- Minimally or Non-invasive Systemic Oxygen Delivery and Carbon Dioxide Removal






DHA SBIR/STTR Process Flow

Phase I
Feasibility Study
\$250K - 6 months

Technical Assistance Advocate (TAA) commercialization readiness assistance

Phase II
Commercialization
Gov./Ind. (no SBIR \$)
No \$ ceiling







DoD SBIR/STTR BAAs

SBIR 24.1 STTR 24.A

Pre-Release 29 NOV 23

> Open 3 JAN 24

> Close 7 FEB 24

SBIR 24.2 STTR 24.B

Pre-Release 17 Apr 24

Open 15 May 24

Close 12 June 24 **SBIR 24.3 STTR 24.C**

Pre-Release 21 Aug 24

Open 18 Sep 24

Close 16 Oct 24 **SBIR 24.4 STTR 24.D**

Pre-Release TBD- Multiple

Open TBD- Multiple

Close TBD- Multiple





Proposal Tips

- Read the BAA thoroughly
- Take advantage of the pre-release period of the Broad Agency Announcement when you can contact topic authors directly
- Don't miss critical Phase II proposal information on the topic
 - You are never just proposing to the Phase I—the Phase I is intended to prove the feasibility of your approach to Phase II
- Phase III is the author's working concept of the future state of the technology, but it is always a good idea to identify additional commercial potential.
- Submit early!
- Ultimately, successful DHA SBIR and STTR efforts must demonstrate a better/faster/cheaper approach with a meaningful non-DoD market and attention to fielding specifics





DHA SBIR/STTR Team

Mr. JR Myers, Project Manager

Ms. Colleen Gibney, Deputy Project Manager

Ms. Dominique Quesada, Operations Manager

Mr. Paul Brohawn, Program Analyst

Ms. Susan Fithian, Program Analyst

Contact us: usarmy.detrick.medcom-usamrmc.mbx.dhpsbir@health.mil





Questions?





